Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention

NCT07276763 · tracked via the Priya Life Science China tracker

Sponsor

Fudan University

Phase

Observational

Started

2025-12-10

Last updated

2025-12-11

Condition(s) studied

Gastric Retention

Investigational drug(s) / intervention(s)

No Intervention: Observational Cohort

No Intervention: Observational Cohort: No Intervention: Observational Cohort

Study summary

A retrospective observational study to explore the impact of discontinuing GLP-1 receptor agonists for two weeks prior to upper endoscopy on the risk of gastric retention

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Undergoing elective upper endoscopy * Complete clinical information available, including endoscopy report, age, sex, BMI, history of diabetes, prior gastric surgery, and gastrointestinal symptom Exclusion Criteria: * Presence of upper gastrointestinal malignancy or obstruction * History of gastric surgery (including ESD, gastrectomy, gastric bypass, etc.) * Emergency endoscopy or non-elective procedures * Missing key clinical information

Primary outcome measure(s)

Proportion of gastric retention — Immediately at study initiation

Trial sites (1)

Facility	City	Region	Status
Huadong hospital, Fudan university	Shanghai	Shanghai Municipality

More Fudan University trials in China

The Safety and Efficacy of Multimodal Thermal Therapy in the Treatment of Early-stage Invasive Breast Cancer Starting soon

Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer Starting soon

an AI-Driven Four-Tier Invasion Depth Classification for Early Esophageal Cancer Active, not recruiting

Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma Starting soon

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) Recruiting

Other trials for the same condition

Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention Starting soon

Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07276763 on ClinicalTrials.gov ↗ ← All trials in China